Bronchodilator therapy for COPD: a 20-year road


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the problem of bronchodilator therapy for chronic obstructive pulmonary disease (COPD). The choice of bronchodilators as a priority in the treatment of patients with COPD is justified by their numerous sanogenetic effects, achieved mainly by a direct stimulating effect on β2-adrenergic receptors and indirectly by blocking the effect of acetylcholine on muscarinic cholinergic receptors (cholinergic blockers or anticholinergic drugs).

Full Text

Restricted Access

About the authors

Aleksandr I. Sinopalnikov

Russian Medical Academy of Continuous Professional Education

Email: aisyn@list.ru
Dr. Sci. (Med.), Professor, Head of the Department of Pulmonology Moscow, Russia

References

  1. Lenfant C. Preface to the 2001 GOLD Report. In: Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic pulmonary disease. NHLBI/WEHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256-76
  2. Berry P.D., Dhand R. Inhalation Therapy for Stable COPD: 20 Years of GOLD Reports. Adv Ther. 2020;37:1812-28. doi: 10.1007/s12325-020-01289-y.
  3. Cazzola M., Page C.P., Calzetta L., et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450-504. doi: 10.1124/pr.111.004580.
  4. Williams D.M., Rubin B.K. Clinical pharmacology of bronchodilator medications. Respir Care. 2018;63:641-54. Doi: 10.4187/ respcare.06051.
  5. Johnson M., Rennard S. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest. 2001;120:258-70. Doi: 10.1378/ chest.120.1.258.
  6. Hanania N.A., Moore R.H. Anti-inflammatory activities of beta2-agonists. Curr Drug Targets Inflamm Allergy. 2004;3:271-77. doi: 10.2174/1568010043343598.
  7. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD, 2021. Available from: http://goldcopd.org/gold- 2021-global-strategy-diagnosis-management-prevention-copd/.
  8. Miravitlles M., Soler-Cataluna J.J., Calle M., et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017: pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53:324-35. doi: 10.1016/j.arbres.2017.03.018.
  9. Aisanov Z., Avdeev S., Arkhipov V., et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int J COPD. 2018;13:183-87. doi: 10.2147/COPD. S153770.
  10. Cazzola M., Molimard M. The scientific rationale for combining long-acting beta-2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23:257-67. Doi: 10.1016/j. pupt.2010.03.003.
  11. Miravitlles M., Baek S., Vithlani V., Lad R. Optimal bronchodilation for COPD patients: are all long-acting ß2-agonist/long-acting muscarinic antagonists the same? Tuberc Respir Dis. 2018;81:198-215. Doi: 10.4046/ trd.2018.0040.
  12. Price D., Östrem A., Thomas M., Welte T. Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review. Int J COPD. 2017;12:141-68. doi: 10.2147/COPD. S116719.
  13. Rodrigo G.J., Price D., Anzueto A., et al. LABA/ LAMA combination versus monotherapy or LABA/ ICS in COPD: a systematic review and meta-analysis. Int J COPD. 2017;12:907-22. doi: 10.2147/COPD.S130482.
  14. Takahashi T., Ichinose M., Inoue H., et al. Underdiagnosis and undertreatment of COPD in primary care settings. Respirol. 2003;8:504-8. doi: 10.1046/j.1440-1843.2003.00501.x.
  15. Zaas D., Wise R., Wiener C. Longcope Spirometry Investigation Team. Airway obstruction is common but unsuspected in patients admitted to a general medicine service. Chest. 2014;125:106-11. doi: 10.1378/chest.125.1.106.
  16. Tantucci C., Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon. Dis. 2012;7:95-9. doi: 10.2147/COPD.S27480.
  17. Troosters T., Sciurba F.C., Decramer M., et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebocontrolled trial. NPJ Prim Care Respir Med. 2014;24:14003. doi: 10.1038/npjpcrm.2014.3.
  18. Covvey J.R., Mullen A.B., Ryan M., et al. A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom. Int J Clin Pract. 2014;68:1200-208. doi: 10.1111/ijcp.12451.
  19. Asai K., Hirata K., Hashimoto S., et al. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: pooled analysis of SHINE and ARISE. Respir Investig. 2016;54:428-35. doi: 10.1016/j.resinv.2016.06.006.
  20. Bateman E.D., Ferguson G.T., Barnes N., et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484-94. doi: 10.1183/09031936.00200212.
  21. Wedzicha J.A., Decramer M., Ficker J.H., et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, doubleblind, parallel-group study. Lancet Respir Med. 2013;1:199-209. doi: 10.1016/S2213-2600(13)70052-3.
  22. Muro S., Yoshisue H., Kostikas K., et al. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis. Respirol. 2020;25:393-400. doi: 10.1111/resp.13651.
  23. Wedzicha J.A., Banerji D., Chapman K.R., et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222-34. Doi: 10.1056/ NEJMoa1516385.
  24. Anzueto A.R., Kostikas K., Mezzi K., et al. Indacaterol/glycopyrronium versus salmeterol/ fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respir Res. 2018;19:121. Doi: 10.1186/ s12931-018-0830-z.
  25. Mammen M.J., Lloyd D.R., Kumar S., et al. Triple therapy versus dual or monotherapy with long-acting bronchodilators for COPD: A systematic review and meta-analysis. Ann Am Thorac Soc. 2020;17(10):1308-18. Doi: 10.1513/ AnnalsATS.202001-023OC.
  26. Bafadhel M., Peterson S., De Blas M.A., et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6:117-26. doi: 10.1016/S2213-2600(18)30006-7.
  27. Gibson P.G. Variability of blood eosinophils as a biomarker in asthma and COPD. Respirol. 2018;23:12-3. doi: 10.1111/resp.13200.
  28. Feldman G.J., Sousa A.R., Lipson D.A., et al. Comparative efficacy of once-daily umeclidinium/ vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34:2518-33. doi: 10.1007/s12325-017-0626-4.
  29. Rogliani P., Calzetta L., Braido F., et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:3115-30. doi: 10.2147/COPD. S170606.
  30. Cazzola M., Matera M.G., Donner C.F. Inhaled ß2-Adrenoceptor Agonists Cardiovascular Safety in Patients with Obstructive Lung Disease. Drugs. 2005;65:1595-610. doi: 10.2165/00003495200565120-00001.
  31. Brodde O.E. Beta1- and beta2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991;43:203-42.
  32. Newton G.E., Parker J.D. Acute effects of beta1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation. 1996;94:353-58. doi: 10.1161/01. cir.94.3.353.
  33. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309-21. Doi: 10.1378/ chest.125.6.2309.
  34. Sears M.R. Adverse effects of beta-agonists. J Allergy Clin Immunol. 2002;110(Suppl. 6):S322-doi: 10.1067/mai.2002.129966.
  35. Cazzola M., Calzetta L., Matera M.G. The cardiovascular risk of tiotropium: is it real? Expert Opin Drug Saf. 2010;9:783-92. doi: 10.1517/14740338.2010.500611.
  36. Yang B., Lin H., Xu C., et al. Choline produces cytoprotective effects against ischemic myocardial injuries: evidence for the role of cardiac m3 subtype muscarinic acetylcholine receptor. Cell Physiol Biochem. 2005;16:163- 74. doi: 10.1159/000089842.
  37. Shi H., Wang H., Lu Y., et al. Choline modulates cardiac membrane repolarization y activating an M3 muscarinic receptor and its coupled K+ channel. J Membr Biol. 1999;169:55-64. doi: 10.1007/pl00005901.
  38. Rogliani P., Calzetta L., Matera M.G., et al. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2019;20:737-50. doi: 10.1080/14656566.2019.1570133.
  39. Vestbo J., Anderson J.A., Brook R.D., et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817-26. Doi: 10.1016/ S0140-6736(16)30069-1.
  40. Buhl R., Magder S., Bothner U., et al. Long-term general and cardiovascular safety of tiotropium/ olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2017;122:58-66. Doi: 10.1016/j. rmed.2016.11.011.
  41. Hohlfeld J.M., Vogel-Claussen J., Biller H., et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a doubleblind, randomised, crossover, placebocontrolled, single-centre trial. Lancet Respir Med. 2018; 6:368-78. doi: 10.1016/S2213-2600(18) 30054-7.
  42. Calzetta L., Matera M.G., Cazzola M. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Opin Pharmacol. 2018;40:95-103. Doi: 10.1016/j. coph.2018.03.011.
  43. Calzetta L., Rogliani P., Matera M.G., et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149:1181-96. doi: 10.1016/j.chest.2016.02.646.
  44. Rogliani P., Matera M.G., Ora J., et al. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J Chron Obstruct Pulmon Dis. 2017;12:3469-85. doi: 10.2147/COPD. S146338.
  45. Chow A.H., Tong H.H., Chattopadhyay P., Shekunov B.Y Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24:411-37. doi: 10.1007/s11095-006-9174-3.
  46. Chapman K.R., Fogarty C.M., Peckitt C., et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. int J Chron Obstruct Pulmon Dis. 2011;6:353-63. doi: 10.2147/COPD.S18529.
  47. Colthorpe P., Voshaar T., Kiekbusch T., et al. 2013. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. J Drug Assess. 2013;2:11-6. doi: 10.3109/21556660.2013.766197.
  48. Lavorini F., Fontana G.A., Usmani O.S. New inhaler devices - the good, the bad and the ugly. Respiration. 2014;88:3-15. doi: 10.1159/000363390.
  49. Riley C.M., Sciurba F.C. Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease. A Review. JAMA. 2019;321:786-97. doi: 10.1001/jama.2019.0131.
  50. Molimard M., Colthorpe P inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners. J Aerosol Med Pulm Drug Deliv. 2015;28:219-28. doi: 10.1089/jamp.2014.1142.
  51. Dolovicha M.B., Kuttlerb A., Dimkeb T.J., Usmanic O.S. Biophysical model to predict lung delivery from a dual bronchodilator dry powder inhaler. int J Pharm. 2019;1:100018. Doi: 10.1016/j. ijpx.2019.100018.
  52. Pavkov R., Mueller S., Fiebich K., et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin. 2010;26:2527-33. doi: 10.1185/03007995.2010.518916.
  53. Molimard M., Raherison C., Lignot S., et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49:1601794. doi: 10.1183/13993003. 01794-2016.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies